Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arbutus Biopharma Corp ABUS

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.


NDAQ:ABUS - Post by User

Bullboard Posts
Post by pool1212on Jun 17, 2011 6:44am
300 Views
Post# 18727785

Working Opportunity fund acquires 563K units of TK

Working Opportunity fund acquires 563K units of TK
As at June 16 2011

The Working Opportunity Fund (EVCC) Ltd. ("WOF"), managed by GrowthWorks(i), announced today that it has acquired in a public offering transaction (the "Offering") 563,000 units (the "Units") of Tekmira Pharmaceuticals Corporation ("Tekmira") at a price of $2.85 per Unit. Each Unit consists of one common share of Tekmira and one half of one common share purchase warrant (the "Warrants"). Each whole Warrant is exercisable for one common share of Tekmira at a price of $3.35 per common share until June 16, 2016. The closing of the Offering occurred after the close of market on June 16, 2011 and the Offering was made pursuant to a prospectus. The common shares of Tekmira are listed on the TSX and NASDAQ. The 563,000 common shares and Warrants, if fully exercised, together with WOF's current holdings of 1,306,467 common shares, represents approximately 17.33% of the issued and outstanding common shares of Tekmira.

GrowthWorks Access Fund Limited Partnership, a GrowthWorks managed fund, did not participate in the Offering and holds 97,953 common shares, representing approximately 0.79% of the issued and outstanding common shares of Tekmira.

As a result of the completion of the Offering, investment funds managed by GrowthWorks(i) now collectively hold an aggregate of 1,967,420 common shares and warrants to purchase 281,500 common shares at a price of CDN$3.35 per common share until June 16, 2016. At present, if the Warrants were fully exercised, investment funds managed by GrowthWorks would hold 2,248,920 common shares of Tekmira, representing approximately 18.12% of the issued and outstanding common shares of Tekmira.

The securities are being held for investment purposes. Although it is not anticipated at this time, investment funds managed by GrowthWorks may make further purchases of securities of Tekmira for investment purposes only.

(i)Matrix Asset Management Inc. ("Matrix") operates its business units through GrowthWorks, Matrix Funds Management(+) and SEAMARK Asset Management Ltd. as separate business units and relies on the relief contained in Part 5 of National Instrument 62-103 in treating portfolio securities owned or controlled within each business unit separately for purposes of early warning, insider reporting and certain other regulatory requirements. In this press release, GrowthWorks refers to companies forming part of the venture capital business unit of Matrix, including: GrowthWorks WV Management Ltd., manager of GrowthWorks Canadian Fund Ltd. and GrowthWorks Commercialization Fund Ltd., GrowthWorks Capital Ltd., manager of WOF, GrowthWorks Access GP I Ltd., general partner of GrowthWorks Access Fund Limited Partnership and GrowthWorks Atlantic Ltd., manager of GrowthWorks Atlantic Venture Fund Ltd. (+)Matrix Funds Management is a division of GrowthWorks Capital Ltd.

Bullboard Posts